<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02383797</url>
  </required_header>
  <id_info>
    <org_study_id>TYH2013336</org_study_id>
    <nct_id>NCT02383797</nct_id>
  </id_info>
  <brief_title>Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox</brief_title>
  <official_title>Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigatoris will carefully select cartilage-hair hypoplasia patients unexposed to
      varicella (VZV) and immunize patients in a controlled manner with VZV vaccine. Patients will
      be selected on the basis of disease severity and the degree of immunodeficiency (including
      CD4+ T-cell counts). Any potential complication of VZV immunization, such as rash, will be
      discussed with the patients/caregivers beforehand and acyclovir will be used to treat any VZV
      related symptoms, consistent with the current practices. The investigators will verify the
      development of immune response to vaccination by testing for VZV antibodies and cell-mediated
      immunity.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Humoral response to vaccination</measure>
    <time_frame>4-6 weeks post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell-mediated response to vaccination</measure>
    <time_frame>4-6 wks post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and severity of adverse events to vaccination</measure>
    <time_frame>0-60 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Cartilage-hair Hypoplasia</condition>
  <arm_group>
    <arm_group_label>Cartilage-hair hypoplasia (CHH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Selected CHH patients will be vaccinated against varicella with Varilrix, one dose of 0,5 ml subcutaneously. If no response is documented to the first dose, the second dose of 0,5 ml can be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varilrix</intervention_name>
    <description>Vaccination against varicella in selected cartilage-hair hypoplasia patients</description>
    <arm_group_label>Cartilage-hair hypoplasia (CHH)</arm_group_label>
    <other_name>ATC J07BK01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  genetically confirmed cartilage-hair hypoplasia diagnosis

          -  age &gt;12 months

          -  no history of chickenpox

          -  informed concent of the patient/caregiver.

        Exclusion Criteria:

          -  positive serum IgG for varicella zoster virus

          -  low CD4+ cell counts (&lt;15% or &lt;200 cells/mm3)

          -  clinical or laboratory signs of severe immunodeficiency

          -  ongoing intravenous or subcutaneous immunoglobulin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Outi Mäkitie, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital and University of Helsinki, Folkhälsan Research Centre, Helsinki Finland</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2015</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Paula Klemetti</investigator_full_name>
    <investigator_title>MD, PhD, Consultant in pediatric gastroenterology and immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Hirschsprung Disease</mesh_term>
    <mesh_term>Osteochondrodysplasias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

